CLINICAL AND RADIOGRAPHIC OUTCOMES AT 2 YEARS AND THE EFFECT OF TOCILIZUMAB DISCONTINUATION FOLLOWING SUSTAINED REMISSION IN THE SECOND AND THIRD YEAR OF THE ACT-RAY STUDY